Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2021 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check if management's own words convey that posture. Look for instances where management describes specific counterparties' own ramps, launches, rollouts, etc., and treats those as drivers of the company's coming activity. Also, the company is already inside that growth, not bidding for it. And the counterparties' trajectory is early and large relative to the company. In the transcript, management discusses several partnerships and customers. For example, the GE Healthcare partnership: "We are currently working together on a new statement of work to begin developing the software infrastructure and architecture that will enable the bidirectional exchange of data between GE's Edison platform and the SOPHiA DDM platform. Our partnership has been going well and we have already seen significant commercial traction in lead sharing." That is about collaboration, but not necessarily about GE's own scaling. More relevant: the DEEP-Lung-IV study. Management says: "Since launching the study in November, 16 sites across six countries have signed up to participate. This should contribute to over half of the 4,000 total patients targeted for enrollment over the course of the study. The demand and appetite we have seen from institutions, including prominent academic centers and hospitals, to join this study has been tremendous, and 13 centers, including UMass, have already been activated." This is about the study's own expansion, but the study is a program the company is running. The counterparties are the sites participating. Management is reporting on the growth of the study's enrollment and site activation. That is a program the company is running, and the company's own volume (analyses) will come from that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.